Iomab-B Makes Actinium Pharma A Rare And Exciting Investment Opportunity

(Click on image to enlarge)


Conclusion

BMT is one of the fastest growing hospital procedures according to AHRQ; US Dept. of HHS. Iomab-B offers a better solution - cheaper, faster, safer, and more effective - than the current standard of care. It also targets a significantly larger patient population because the drug acts as both an induction and conditioning agent, potentially allowing those with active disease to progress to an allogeneic transplant. KOL interest in the drug is high and the company has partnered with some of the leading BMT centers in the U.S. to enroll patients in SIERRA. This is likely why the EMA agreed to accept the data for regulatory filings in Europe.

We are likely to see an interim safety update from the data monitoring committee (DMC) once the first 25% of patients in SIERRA receive treatment. I expect this to occur in the next few months. Two more safety updates at 50% and 75% completion are expected to follow months later, with the top-line data from SIERRA likely during the first half of 2019. I think this will be a major transformative event for Actinium Pharmaceuticals and shareholders.

1 2 3 4 5
View single page >> |

Disclaimer: BioNap is NOT an Investment Advisor. We are an investor intelligence and strategic advisory firm. Most of the companies mentioned on this blog are party to a services ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.